Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter blood thinner course after birth may be just as safe

NCT ID NCT05058924

Disease control Sponsor: Mount Sinai Hospital, Canada Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether a shorter course of blood thinner (LMWH) followed by aspirin is as good as the standard 6 weeks of LMWH for preventing blood clots after childbirth. The study enrolled 30 women at moderate to high risk of clots. The main goal was to see if women would agree to join and stick with the treatment, not to measure clot prevention directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low molecular weight heparin (LMWH) and low-dose aspirin
What this could lead to
If successful, this could point to a shorter, more convenient way to prevent dangerous blood clots after childbirth, reducing the need for daily injections.
What could go wrong
This is a very small pilot study with only 30 participants, so results may not apply to everyone. The study focuses on feasibility, not on proving the treatment works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Aug 2021

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Personal history of unprovoked VTE prior to pregnancy or hormone associated VTE and not prescribed therapeutic anticoagulation or 2. Family history (1st degree relative) of VTE and antithrombin deficiency, protein C or protein S deficiency or 3. Combined thrombophilia or homozygous for the factor V Leiden mutation or prothrombin gene mutation, and family history of VTE (1st degree relative) and 4. \> 18 years of age. Exclusion Criteria: 1. Pre-existing indication for therapeutic LMWH 2. Contraindication to ASA: 1. Known ASA allergy 2. Documented history of gastrointestinal ulcer 3. Known platelet count \< 50x10\^9/L at any time during the current pregnancy or postpartum 3. Contraindication to LMWH, e.g. known allergy 4. Active bleeding at any site, excluding physiological vaginal bleeding 5. Patients with bleeding disorders 6. Known severe hypertension (SBP \>200mm/hg and/or DBP \>120mm/hg) during the current pregnancy or postpartum

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

Contacts and locations

Locations

  • Mount Sinai Hospital

    Toronto, Ontario, M5G 1Z5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.